<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107770">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128763</url>
  </required_header>
  <id_info>
    <org_study_id>UPenn IRB Protocol 816490</org_study_id>
    <secondary_id>U10EY022879</secondary_id>
    <secondary_id>U10EY022881</secondary_id>
    <nct_id>NCT02128763</nct_id>
  </id_info>
  <brief_title>Dry Eye Assessment and Management Study</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Dry Eye Assessment and Management Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the DREAM study is to evaluate the effectiveness and safety of
      supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry
      eye disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to:

        -  Test the hypothesis that  omega-3 supplementation is an effective treatment for Dry Eye
           Disease (DED) in Primary Clinical Trial.

        -  Better understand DED by describing and evaluating a comprehensive set of features of
           DED and treatment over 12 months of observation in a well-characterized group of
           patients.

        -  Determine the effects of extended use and discontinuation of omega-3 through the
           Extension trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean of change from baseline in OSDI score at 6 and 12 months (Primary  Trial).     Mean of change from 12 months in OSDI score at 18 and 24 months (Extension Study)</measure>
    <time_frame>12 months and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance with the study treatment protocol as measured by changes in blood levels of fatty acids and pill counts</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Greater than or equal to 10 point change in OSDI</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in conjunctival staining score</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corneal fluorescein staining score</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tear film break up time</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Schirmer's test mm</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in use of artificial tears and other treatments for dry eye disease</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 score</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Brief Ocular Discomfort Index score</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in healthcare utilization costs</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cost effectiveness between groups on active and placebo supplements</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of ocular and systemic adverse events</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in IOP</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in contrast sensitivity</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in meibomian gland secretion</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in tear break up time by keratography</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in tear meniscus height by keratography</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in redness by keratography</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in meibography by keratography</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in tear osmolarity</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in tear cytokine level</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in ocular surface cell HLA-DR expression</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Omega-3 supplements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olive oil-5 gelcaps per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 supplements</intervention_name>
    <description>2000 mg EPA and 1000 mg DHA per day</description>
    <arm_group_label>Omega-3 supplements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olive oil gelcaps manufactured to mimic Omega-3 gelcaps</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 2 of the following 4 signs in the same eye at screening and
             baseline visits (Same signs must be present at Screening and Baseline visits):
             Conjunctival staining present greater than or equal to 1 (out of possible score of 6
             per eye), Corneal fluorescein staining present greater than or equal to 4 (out of a
             possible score of 15 per eye), Tear film break up time (TBUT) less than or equal to 7
             seconds, Schirmer's test  greater than or equal to 1 to  less than or equal to 7 mm
             in 5 minutes.

          -  Ocular Surface Disease Index (OSDI) score:  25-80 at screening, 21-80 at baseline.

          -  Symptoms of DED for greater than or equal to 6 months.

          -  Use of or desire to use artificial tears at least 2 times per day in preceding 2
             weeks.

          -  Ability to swallow large, soft gelcaps

        Exclusion Criteria:

          -  Allergic to ingredients in supplements or placebo

          -  Contact lens wear

          -  Pregnant, nursing, or lactating

          -  Current ocular infection, inflammation, or acute allergic conjunctivitis

          -  History of: ocular herpetic keratitis, ocular surgery in past 6 months, LASIK
             surgery, use of glaucoma medicine or surgery for glaucoma, liver disease, atrial
             fibrillation, hemophilia or bleeding tendencies

          -  Currently on anticoagulation therapy

          -  Eyelid abnormalities or extensive ocular scarring

          -  Use of EPA/DHA supplements in excess of 1200 mg per dayi

          -  Current use, insufficient washout period, or intent to change specific treatments for
             dry eye disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny A Asbell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Sinai Icahn School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maureen G Maguire, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Milton M. Hom, OD, FAAO</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milton Hom, OD</last_name>
      <email>eyemage@aaahawk.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Berkeley</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meng Lin, OD</last_name>
      <email>mlin@berkeley.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pendleton Eye Center</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Pendleton, MD</last_name>
      <email>md@pendletoneye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter C. Donshik, MD, PC</name>
      <address>
        <city>Bloomfield</city>
        <state>Connecticut</state>
        <zip>06002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Donshik, MD</last_name>
      <email>pdonshik@snet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Care Centers Management, Inc.</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harvey DuBiner, MD</last_name>
      <email>helendubiner@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University-Eugene and Marilyn Glick Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clark Springs, MD</last_name>
      <email>jhoop@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Kelley, OD</last_name>
      <email>kathykelley@pricevisiongroup.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KU Eye Center</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Sutphin, MD</last_name>
      <email>jsutphin@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reza Dana, MD</last_name>
      <email>reza.dana@schepens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Eye Research of Boston</name>
      <address>
        <city>Winchester</city>
        <state>Massachusetts</state>
        <zip>01890</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jack Greiner, DO</last_name>
      <email>greiner@vision.eri.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roni Shtein, MD</last_name>
      <email>ronim@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, P.A.</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Hardten, MD</last_name>
      <email>drhardten@mneye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Tauber, MD</last_name>
      <email>jt@taubereye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Silverstein, MD</last_name>
      <email>ssilverstein@silversteineyecenters.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Penny Asbell, MD</last_name>
      <email>penny.asbell@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universtity of Rochester-Flaum Eye Institute</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holly Hindman</last_name>
      <email>Kari_steinmetz@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Shore Eye Care, LLP</name>
      <address>
        <city>Wantagh</city>
        <state>New York</state>
        <zip>11793</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jodi Luchs, MD</last_name>
      <email>jluchs@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Westbury</city>
        <state>New York</state>
        <zip>11590</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Perry, MD</last_name>
      <email>hperry@ocli.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vatinee Bunya, MD</last_name>
      <email>Vatinee.Bunya@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Christensen, OD</last_name>
      <email>mchristensen@sco.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>April 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Maureen Maguire</investigator_full_name>
    <investigator_title>Coordinating Center PI</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
